UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Management of pregnancy complicated by Rhesus (D) alloimmunization

Author
Kenneth J Moise Jr, MD
Section Editor
Charles J Lockwood, MD, MHCM
Deputy Editor
Vanessa A Barss, MD, FACOG

INTRODUCTION

Despite the development and implementation of anti-D immune globulin prophylaxis, hemolytic disease of the fetus and newborn due to maternal Rh(D) alloimmunization continues to occur worldwide. Ideally, pregnancies complicated by alloimmunization should be managed by a maternal-fetal medicine specialist with appropriate experience and credentialed to perform the invasive diagnostic and therapeutic procedures that may be needed. With appropriate pregnancy monitoring and intervention, this disorder can be treated successfully in almost all cases, with minimal long-term sequelae in offspring.

This topic will provide our approach to management of pregnant women with Rh(D) alloimmunization. Related topics, including a discussion of the Rhesus system, diagnosis and prevention of Rh(D) alloimmunization, diagnosis and management of pregnant women with non-Rh(D) alloimmunization, in utero transfusion, and neonatal issues, are reviewed in detail separately:

(See "Overview of Rhesus D alloimmunization in pregnancy".)

(See "Management of non-Rh(D) red blood cell alloantibodies during pregnancy".)

(See "Intrauterine fetal transfusion of red cells".)

                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Nov 21 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012; 120:1132.
  2. Anderson KG. How well does paternity confidence match actual paternity? Evidence from worldwide nonpaternity rates. Current Anthropology 2006; 47:513.
  3. Pirelli KJ, Pietz BC, Johnson ST, et al. Molecular determination of RHD zygosity: predicting risk of hemolytic disease of the fetus and newborn related to anti-D. Prenat Diagn 2010; 30:1207.
  4. Mackie FL, Hemming K, Allen S, et al. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG 2016.
  5. Wikman AT, Tiblad E, Karlsson A, et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012; 120:227.
  6. Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype. Blood 2000; 95:12.
  7. Tynan JA, Angkachatchai V, Ehrich M, et al. Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RHD testing. Am J Obstet Gynecol 2011; 204:251.e1.
  8. Daniels G, van der Schoot CE, Olsson ML. Report of the First International Workshop on molecular blood group genotyping. Vox Sang 2005; 88:136.
  9. Bombard AT, Akolekar R, Farkas DH, et al. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn 2011; 31:802.
  10. Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002; 42:1079.
  11. White HE, Dent CL, Hall VJ, et al. Evaluation of a novel assay for detection of the fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive prenatal diagnosis. PLoS One 2012; 7:e45073.
  12. van den Oever JM, Balkassmi S, Segboer T, et al. Mrassf1a-pap, a novel methylation-based assay for the detection of cell-free fetal DNA in maternal plasma. PLoS One 2013; 8:e84051.
  13. Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006; 52:2211.
  14. Moise KJ. Fetal RhD typing with free DNA in maternal plasma. Am J Obstet Gynecol 2005; 192:663.
  15. Thurik FF, Ait Soussan A, Bossers B, et al. Analysis of false-positive results of fetal RHD typing in a national screening program reveals vanishing twins as potential cause for discrepancy. Prenat Diagn 2015; 35:754.
  16. Bianchi DW, Avent ND, Costa JM, van der Schoot CE. Noninvasive prenatal diagnosis of fetal Rhesus D: ready for Prime(r) Time. Obstet Gynecol 2005; 106:841.
  17. Goebel JC, Soergel P, Pruggmayer M, et al. Prenatal diagnosis of the Rhesus D fetal blood type on amniotic fluid in daily practice. Arch Gynecol Obstet 2008; 277:155.
  18. Moise KJ Jr, Carpenter RJ Jr. Increased severity of fetal hemolytic disease with known rhesus alloimmunization after first-trimester transcervical chorionic villus biopsy. Fetal Diagn Ther 1990; 5:76.
  19. de Silva M, Contreras M, Mollison PL. Failure of passively administered anti-Rh to prevent secondary Rh responses. Vox Sang 1985; 48:178.
  20. Bowman JM, Pollock JM. Reversal of Rh alloimmunization. Fact or fancy? Vox Sang 1984; 47:209.
  21. Nicolaides KH, Rodeck CH. Maternal serum anti-D antibody concentration and assessment of rhesus isoimmunisation. BMJ 1992; 304:1155.
  22. Picklesimer AH, Oepkes D, Moise KJ Jr, et al. Determinants of the middle cerebral artery peak systolic velocity in the human fetus. Am J Obstet Gynecol 2007; 197:526.e1.
  23. Pretlove SJ, Fox CE, Khan KS, Kilby MD. Noninvasive methods of detecting fetal anaemia: a systematic review and meta-analysis. BJOG 2009; 116:1558.
  24. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9.
  25. Zimmerman R, Carpenter RJ Jr, Durig P, Mari G. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat. BJOG 2002; 109:746.
  26. LILEY AW. Liquor amnil analysis in the management of the pregnancy complicated by resus sensitization. Am J Obstet Gynecol 1961; 82:1359.
  27. Queenan JT, Tomai TP, Ural SH, King JC. Deviation in amniotic fluid optical density at a wavelength of 450 nm in Rh-immunized pregnancies from 14 to 40 weeks' gestation: a proposal for clinical management. Am J Obstet Gynecol 1993; 168:1370.
  28. Oepkes D, Seaward PG, Vandenbussche FP, et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med 2006; 355:156.
  29. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Mari G, Norton ME, et al. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia--diagnosis and management. Am J Obstet Gynecol 2015; 212:697.
  30. Mari G, Abuhamad AZ, Cosmi E, et al. Middle cerebral artery peak systolic velocity: technique and variability. J Ultrasound Med 2005; 24:425.
  31. Sallout BI, Fung KF, Wen SW, et al. The effect of fetal behavioral states on middle cerebral artery peak systolic velocity. Am J Obstet Gynecol 2004; 191:1283.
  32. Shono M, Shono H, Ito Y, et al. The effect of behavioral states on fetal heart rate and middle cerebral artery flow-velocity waveforms in normal full-term fetuses. Int J Gynaecol Obstet 1997; 58:275.
  33. ACOG practice bulletin. Antepartum fetal surveillance. Number 9, October 1999 (replaces Technical Bulletin Number 188, January 1994). Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet 2000; 68:175.
  34. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008; 112:164.
  35. Nicolaides KH, Soothill PW, Clewell WH, et al. Fetal haemoglobin measurement in the assessment of red cell isoimmunisation. Lancet 1988; 1:1073.
  36. Klumper FJ, van Kamp IL, Vandenbussche FP, et al. Benefits and risks of fetal red-cell transfusion after 32 weeks gestation. Eur J Obstet Gynecol Reprod Biol 2000; 92:91.
  37. MacKenzie IZ, MacLean DA, Fry A, Evans SL. Midtrimester intrauterine exchange transfusion of the fetus. Am J Obstet Gynecol 1982; 143:555.
  38. Papantoniou N, Sifakis S, Antsaklis A. Therapeutic management of fetal anemia: review of standard practice and alternative treatment options. J Perinat Med 2013; 41:71.
  39. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016; 31:149.
  40. Spong CY, Porter AE, Queenan JT. Management of isoimmunization in the presence of multiple maternal antibodies. Am J Obstet Gynecol 2001; 185:481.
  41. Nordvall M, Dziegiel M, Hegaard HK, et al. Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion 2009; 49:2070.
  42. Markham KB, Rossi KQ, Nagaraja HN, O'Shaughnessy RW. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. Am J Obstet Gynecol 2015; 213:68.e1.
  43. Seeho SK, Burton G, Leigh D, et al. The role of preimplantation genetic diagnosis in the management of severe rhesus alloimmunization: first unaffected pregnancy: case report. Hum Reprod 2005; 20:697.